diazoxide has been researched along with Diabetes Mellitus, Type 1 in 20 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Individuals with long-standing type 1 diabetes (T1D) are at increased risk of severe hypoglycemia secondary to impairments in normal glucose counterregulatory responses (CRRs)." | 6.80 | Diazoxide improves hormonal counterregulatory responses to acute hypoglycemia in long-standing type 1 diabetes. ( George, PS; McCrimmon, RJ; Palmer, CN; Tavendale, R, 2015) |
| "Right atrial sections from four patient groups-non-diabetic, insulin-dependent diabetes mellitus (IDDM), non-insulin-dependent diabetes mellitus (NIDDM) receiving glibenclamide, and NIDDM receiving metformin-were subjected to one of the following protocols: aerobic control, simulated ischemia/reoxygenation, ischemic preconditioning before ischemia, and pharmacological preconditioning with alpha 1 agonist phenylephrine, adenosine, the mito-K(ATP) channel opener diazoxide, the protein kinase C (PKC) activator phorbol-12-myristate-13-acetate (PMA), or the p38 mitogen-activated protein kinase (p38MAPK) activator anisomycin." | 3.73 | Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. ( Fowler, A; Galiñanes, M; Hassouna, A; Loubani, M; Matata, BM; Standen, NB, 2006) |
| "Individuals with long-standing type 1 diabetes (T1D) are at increased risk of severe hypoglycemia secondary to impairments in normal glucose counterregulatory responses (CRRs)." | 2.80 | Diazoxide improves hormonal counterregulatory responses to acute hypoglycemia in long-standing type 1 diabetes. ( George, PS; McCrimmon, RJ; Palmer, CN; Tavendale, R, 2015) |
| "Diazoxide treatment reduced A1C from 8." | 2.75 | Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control. ( Dørflinger, GH; Grill, V; Hals, I; Kollind, M; Moen, T; Nermoen, I; Radtke, MA; Skeie, S; Svartberg, J; Sørheim, JI, 2010) |
| "Diazoxide was given to six patients during a 7-day period (100 mg three times daily), followed by a 3-week washout." | 2.69 | Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxide. ( Berne, C; Björk, E; Karlsson, FA, 1998) |
| "Type 1 diabetes is the result of a chronic inflammatory process that causes elimination of insulin-producing beta-cells, resulting in insulin deficiency and hyperglycemia." | 2.41 | Beta-cell activity and destruction in type 1 diabetes. ( Berne, C; Björk, E; Karlsson, FA; Kullin, M; Li, Z; Ma, JY; Schölin, A; Zhao, L, 2000) |
| "Diazoxide was commenced in 28 patients (82." | 1.72 | Clinical and genetic heterogeneity of HNF4A/HNF1A mutations in a multicentre paediatric cohort with hyperinsulinaemic hypoglycaemia. ( Brusgaard, K; Christesen, H; Conlon, N; Dastamani, A; Demirbilek, H; Flanagan, SE; Gubaeva, D; Houghton, JAL; McGlacken-Byrne, SM; Melikyan, M; Mohammad, JK; Murphy, NP; Schou, AJ; Shah, P; Siersbæk, J, 2022) |
| "Eight weeks after type 1 diabetes induction, DZ preconditioned, and non-preconditioned DM-EPCs were transplanted into left ventricle of diabetic rats (at a dose of 2 × 10(6) DM-EPCs/70 μl serum free medium)." | 1.42 | Diazoxide preconditioning of endothelial progenitor cells from streptozotocin-induced type 1 diabetic rats improves their ability to repair diabetic cardiomyopathy. ( Ali, M; Anjum, MS; Khan, SN; Mehmood, A; Riazuddin, S; Tarrar, MN, 2015) |
| "Insulin-dependent diabetes mellitus (IDDM) is associated with the formation of autoantibodies against different antigens in the islets of Langerhans, so-called islet cell antibodies (ICA)." | 1.29 | Modulation of beta-cell activity and its influence on islet cell antibody (ICA) and islet cell surface antibody (ICSA) reactivity. ( Björk, E; Grawé, J; Hallberg, A; Kämpe, O; Karlsson, FA; Norheim, I, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| McGlacken-Byrne, SM | 1 |
| Mohammad, JK | 1 |
| Conlon, N | 1 |
| Gubaeva, D | 1 |
| Siersbæk, J | 1 |
| Schou, AJ | 1 |
| Demirbilek, H | 1 |
| Dastamani, A | 1 |
| Houghton, JAL | 1 |
| Brusgaard, K | 1 |
| Melikyan, M | 1 |
| Christesen, H | 1 |
| Flanagan, SE | 1 |
| Murphy, NP | 1 |
| Shah, P | 1 |
| Welters, A | 1 |
| Meissner, T | 2 |
| Grulich-Henn, J | 1 |
| Fröhlich-Reiterer, E | 1 |
| Warncke, K | 1 |
| Mohnike, K | 1 |
| Blankenstein, O | 1 |
| Menzel, U | 1 |
| Datz, N | 1 |
| Bollow, E | 1 |
| Holl, RW | 1 |
| George, PS | 1 |
| Tavendale, R | 1 |
| Palmer, CN | 1 |
| McCrimmon, RJ | 1 |
| Ali, M | 1 |
| Mehmood, A | 1 |
| Anjum, MS | 1 |
| Tarrar, MN | 1 |
| Khan, SN | 1 |
| Riazuddin, S | 1 |
| Grill, V | 2 |
| Radtke, M | 1 |
| Qvigstad, E | 1 |
| Kollind, M | 2 |
| Björklund, A | 1 |
| Radtke, MA | 1 |
| Nermoen, I | 1 |
| Skeie, S | 1 |
| Sørheim, JI | 1 |
| Svartberg, J | 1 |
| Hals, I | 1 |
| Moen, T | 1 |
| Dørflinger, GH | 1 |
| Chen, ZC | 1 |
| Cheng, YZ | 1 |
| Chen, LJ | 1 |
| Cheng, KC | 1 |
| Li, Y | 1 |
| Cheng, J | 1 |
| Wendel, U | 1 |
| Burgard, P | 1 |
| Schaetzle, S | 1 |
| Mayatepek, E | 1 |
| Ortqvist, E | 1 |
| Björk, E | 6 |
| Wallensteen, M | 1 |
| Ludvigsson, J | 1 |
| Aman, J | 1 |
| Johansson, C | 1 |
| Forsander, G | 1 |
| Lindgren, F | 1 |
| Berglund, L | 1 |
| Bengtsson, M | 1 |
| Berne, C | 4 |
| Persson, B | 1 |
| Karlsson, FA | 6 |
| Hassouna, A | 1 |
| Loubani, M | 1 |
| Matata, BM | 1 |
| Fowler, A | 1 |
| Standen, NB | 1 |
| Galiñanes, M | 1 |
| Kämpe, O | 2 |
| Grawé, J | 1 |
| Hallberg, A | 1 |
| Norheim, I | 1 |
| Williams, AJ | 1 |
| Beales, PE | 1 |
| Krug, J | 1 |
| Procaccini, E | 1 |
| Signore, A | 1 |
| Xu, S | 1 |
| Gale, EA | 1 |
| Pozzilli, P | 1 |
| Wibell, L | 1 |
| Oskarsson, P | 1 |
| Rasmussen, SB | 1 |
| Sørensen, TS | 1 |
| Hansen, JB | 1 |
| Mandrup-Poulsen, T | 1 |
| Hornum, L | 1 |
| Markholst, H | 1 |
| Kullin, M | 1 |
| Li, Z | 1 |
| Ma, JY | 1 |
| Schölin, A | 1 |
| Zhao, L | 1 |
| Gossain, VV | 1 |
| Werk, EE | 1 |
| Sholiton, LJ | 1 |
| Srivastava, L | 1 |
| Knowles, HC | 1 |
| Bleicher, SJ | 1 |
| Chowdhury, F | 1 |
| Podolsky, S | 1 |
| Fleishman, P | 1 |
| Goldner, MG | 1 |
| Söling, HD | 1 |
| Unger, KO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Diazoxide in Acute Hypoglycaemia[NCT01488136] | Phase 4 | 12 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for diazoxide and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Beneficial effects of K-ATP channel openers in diabetes: an update on mechanisms and clinical experiences.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diazoxide; Humans; Hypoglycemic Agents; Insuli | 2009 |
Beta-cell rest: a strategy for the prevention of autoimmune diabetes.
Topics: Autoantibodies; Autoantigens; Diabetes Mellitus, Type 1; Diazoxide; Disease Progression; Gene Expres | 1997 |
Beta-cell activity and destruction in type 1 diabetes.
Topics: Animals; Autoantigens; Diabetes Mellitus, Type 1; Diazoxide; Humans; Islets of Langerhans; Mice; Oct | 2000 |
5 trials available for diazoxide and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Diazoxide improves hormonal counterregulatory responses to acute hypoglycemia in long-standing type 1 diabetes.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 1; Diazoxide; Double-Blind Method; Female; Genotype; Huma | 2015 |
Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control.
Topics: Adult; Antihypertensive Agents; Autoimmunity; Blood Glucose; Body Weight; Circadian Rhythm; Diabetes | 2010 |
Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes.
Topics: Adolescent; C-Peptide; Child; Diabetes Mellitus, Type 1; Diazoxide; Female; Humans; Hypoglycemic Age | 2004 |
Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes.
Topics: Adult; Autoantibodies; C-Peptide; Diabetes Mellitus, Type 1; Diazoxide; Drug Therapy, Combination; F | 1996 |
Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxide.
Topics: Adult; Antihypertensive Agents; Blood Glucose; C-Peptide; Data Interpretation, Statistical; Diabetes | 1998 |
12 other studies available for diazoxide and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Clinical and genetic heterogeneity of HNF4A/HNF1A mutations in a multicentre paediatric cohort with hyperinsulinaemic hypoglycaemia.
Topics: Adolescent; Birth Weight; Child; Child, Preschool; Cohort Studies; Diabetes Mellitus, Type 1; Diabet | 2022 |
Characterization of diabetes following pancreatic surgery in patients with congenital hyperinsulinism.
Topics: Adolescent; Blood Glucose; C-Peptide; Child; Child, Preschool; Congenital Hyperinsulinism; Diabetes | 2018 |
Diazoxide preconditioning of endothelial progenitor cells from streptozotocin-induced type 1 diabetic rats improves their ability to repair diabetic cardiomyopathy.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers; Blood Glucose; Cell Proliferation; Ce | 2015 |
Increase of ATP-sensitive potassium (K(ATP)) channels in the heart of type-1 diabetic rats.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Animals; ATP-Binding Cassette Transporters; | 2012 |
Long-term follow-up of 114 patients with congenital hyperinsulinism.
Topics: Adolescent; Age of Onset; Child; Child, Preschool; Developmental Disabilities; Diabetes Mellitus, Ty | 2003 |
Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium.
Topics: Adenosine; Adrenergic alpha-Agonists; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitu | 2006 |
Modulation of beta-cell activity and its influence on islet cell antibody (ICA) and islet cell surface antibody (ICSA) reactivity.
Topics: Animals; Autoantibodies; Diabetes Mellitus, Type 1; Diazoxide; Flow Cytometry; Glipizide; Humans; Im | 1993 |
Tolbutamide reduces the incidence of diabetes mellitus, but not insulitis, in the non-obese-diabetic mouse.
Topics: Aging; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diazoxide; Female; Insulin; Islets of Lang | 1993 |
Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cell function and mass in acutely diabetic BB rats.
Topics: Animals; Arginine; Blood Glucose; C-Peptide; Cells, Cultured; Diabetes Mellitus, Type 1; Diazoxide; | 2000 |
Plasma renin activity in juvenile diabetes mellitus and effect of diazoxide.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diazoxid | 1975 |
Studies on diazoxide-induced hyperglycemia: an extrapancreatic mechanism.
Topics: Adenoma, Islet Cell; Adult; Aged; Blood Glucose; Child; Coloring Agents; Diabetes Mellitus; Diabetes | 1968 |
The role of insulin in the regulation of -amylase synthesis in the rat pancreas.
Topics: Adrenalectomy; Amino Sugars; Amylases; Animals; Anti-Bacterial Agents; Chymotrypsin; Dactinomycin; D | 1972 |